Do analysts rate CALT or ERAS?

Erasca has a consensus price target of $20.11, suggesting a potential upside of 9.78%. Given Erasca's stronger consensus rating and higher probable upside, analysts clearly believe Erasca is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Erasca 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60

Do analysts prefer INDV or CALT?

Indivior presently has a consensus target price of $40.29, suggesting a potential downside of 1.81%. Given Indivior's stronger consensus rating and higher probable upside, equities research analysts plainly believe Indivior is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate CALT or MANE?

Veradermics has a consensus price target of $114.20, suggesting a potential downside of 7.34%. Given Veradermics' stronger consensus rating and higher probable upside, analysts plainly believe Veradermics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Veradermics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has better earnings and valuation, CALT or MANE?

Veradermics has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Calliditas Therapeutics AB (publ) $1.60B 0.74 -$43.96M -$1.85 N/A Veradermics N/A N/A N/A N/A N/A

Do analysts rate TNGX or CALT?

Tango Therapeutics currently has a consensus target price of $41.50, suggesting a potential upside of 32.76%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tango Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.73 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Calliditas Therapeutics AB (publ) (CALT) Competitors

$40.00 0.00 (0.00%)

As of 06/29/2026

Compare

CALT vs. ERAS, INDV, KNSA, MANE, and TNGX

Should you buy Calliditas Therapeutics AB (publ) stock or one of its competitors? MarketBeat compares Calliditas Therapeutics AB (publ) with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Calliditas Therapeutics AB (publ) include Erasca (ERAS), Indivior (INDV), Kiniksa Pharmaceuticals International (KNSA), Veradermics (MANE), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.

How does Calliditas Therapeutics AB (publ) compare to Erasca?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Erasca has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Erasca has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Erasca's return on equity of -35.31% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Erasca	N/A	-35.31%	-29.49%

In the previous week, Erasca had 31 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 31 mentions for Erasca and 0 mentions for Calliditas Therapeutics AB (publ). Erasca's average media sentiment score of 0.03 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Erasca is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Erasca	Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Erasca. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Erasca has a consensus price target of $20.11, suggesting a potential upside of 9.78%. Given Erasca's stronger consensus rating and higher probable upside, analysts clearly believe Erasca is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Erasca beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Indivior (NASDAQ:INDV) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

60.3% of Indivior shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Indivior presently has a consensus target price of $40.29, suggesting a potential downside of 1.81%. Given Indivior's stronger consensus rating and higher probable upside, equities research analysts plainly believe Indivior is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Indivior has a net margin of 19.44% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

In the previous week, Indivior had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Indivior and 0 mentions for Calliditas Therapeutics AB (publ). Indivior's average media sentiment score of 0.57 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Indivior is being referred to more favorably in the media.

Company	Overall Sentiment
Indivior	Positive
Calliditas Therapeutics AB (publ)	Neutral

Indivior has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Indivior has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	4.04	$210M	$1.95	21.04
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Summary

Indivior beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Kiniksa Pharmaceuticals International?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kiniksa Pharmaceuticals International has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Kiniksa Pharmaceuticals International	$677.56M	7.26	$59.01M	$0.90	71.06

Kiniksa Pharmaceuticals International has a consensus price target of $62.71, suggesting a potential downside of 1.93%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher possible upside, analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Kiniksa Pharmaceuticals International had 7 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 7 mentions for Kiniksa Pharmaceuticals International and 0 mentions for Calliditas Therapeutics AB (publ). Kiniksa Pharmaceuticals International's average media sentiment score of 1.28 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Kiniksa Pharmaceuticals International	Positive

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market.

Summary

Kiniksa Pharmaceuticals International beats Calliditas Therapeutics AB (publ) on 15 of the 17 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Veradermics (NYSE:MANE) are both pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Veradermics' average media sentiment score of 1.00 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Veradermics is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Veradermics	Positive

Veradermics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Veradermics' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Veradermics	N/A	N/A	N/A

Veradermics has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ).

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

Veradermics has a consensus price target of $114.20, suggesting a potential downside of 7.34%. Given Veradermics' stronger consensus rating and higher probable upside, analysts plainly believe Veradermics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Veradermics beats Calliditas Therapeutics AB (publ) on 7 of the 10 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	72.49	-$101.59M	-$0.83	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

In the previous week, Tango Therapeutics had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Tango Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Tango Therapeutics' average media sentiment score of 1.43 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tango Therapeutics	Positive
Calliditas Therapeutics AB (publ)	Neutral

Tango Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Tango Therapeutics currently has a consensus target price of $41.50, suggesting a potential upside of 32.76%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tango Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Tango Therapeutics beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALT vs. The Competition

Export

Metric	Calliditas Therapeutics AB (publ)	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.19B	$1.00B	$7.07B	$12.45B
Dividend Yield	N/A	4.84%	2.66%	6.16%
P/E Ratio	-21.62	1.47	27.27	24.87
Price / Sales	0.74	118.59	544.68	102.84
Price / Cash	N/A	20.06	48.53	58.59
Price / Book	37.74	8.12	10.95	6.54
Net Income	-$43.96M	-$3.83M	$3.57B	$336.70M
7 Day Performance	N/A	2.80%	2.29%	2.81%
1 Month Performance	N/A	1.71%	1.36%	0.58%
1 Year Performance	N/A	50.48%	36.68%	31.29%

Calliditas Therapeutics AB (publ) Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
ERAS Erasca	1.7076 of 5 stars	$15.07 -0.1%	$20.11 +33.5%	+1,342.5%	$4.69B	N/A	N/A	120	Trending News
INDV Indivior	2.1289 of 5 stars	$39.97 +4.3%	$40.29 +0.8%	+178.4%	$4.67B	$1.24B	20.50	1,051
KNSA Kiniksa Pharmaceuticals International	3.0866 of 5 stars	$59.49 +4.1%	$60.86 +2.3%	+131.1%	$4.40B	$754.05M	66.10	220	News Coverage Positive News Analyst Forecast
MANE Veradermics	N/A	$103.88 +1.1%	$114.20 +9.9%	N/A	$4.29B	N/A	N/A	19	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALT) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. ERAS, INDV, KNSA, MANE, and TNGX

How does Calliditas Therapeutics AB (publ) compare to Erasca?

Summary

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Summary

How does Calliditas Therapeutics AB (publ) compare to Kiniksa Pharmaceuticals International?

Summary

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Summary

How does Calliditas Therapeutics AB (publ) compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. ERAS, INDV, KNSA, MANE, and TNGX

How does Calliditas Therapeutics AB (publ) compare to Erasca?

Which has more risk & volatility, CALT or ERAS?

Is CALT or ERAS more profitable?

Does the media favor CALT or ERAS?

Which has stronger valuation & earnings, CALT or ERAS?

Do analysts rate CALT or ERAS?

Do institutionals and insiders hold more shares of CALT or ERAS?

Summary

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Do institutionals and insiders hold more shares of INDV or CALT?

Do analysts prefer INDV or CALT?

Is INDV or CALT more profitable?

Does the media favor INDV or CALT?

Which has more volatility and risk, INDV or CALT?

Which has higher earnings and valuation, INDV or CALT?

Summary

How does Calliditas Therapeutics AB (publ) compare to Kiniksa Pharmaceuticals International?

Do institutionals and insiders have more ownership in CALT or KNSA?

Which has preferable valuation and earnings, CALT or KNSA?

Do analysts rate CALT or KNSA?

Does the media prefer CALT or KNSA?

Is CALT or KNSA more profitable?

Which has more risk and volatility, CALT or KNSA?

Summary

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Do insiders & institutionals have more ownership in CALT or MANE?

Does the media prefer CALT or MANE?

Is CALT or MANE more profitable?

Which has better earnings and valuation, CALT or MANE?

Do analysts rate CALT or MANE?

Summary

How does Calliditas Therapeutics AB (publ) compare to Tango Therapeutics?

Do institutionals and insiders hold more shares of TNGX or CALT?

Which has stronger valuation and earnings, TNGX or CALT?

Does the media prefer TNGX or CALT?

Which has more volatility & risk, TNGX or CALT?

Is TNGX or CALT more profitable?

Do analysts rate TNGX or CALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools